Press Releases

STATEN ISLAND, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- Please note in a release issued on April 30, 2024 by ES Bancshares, that the 1Q23 data column in the Key Quarterly Financial Data table was incorrect. The amended release follows:

ES Bancshares, Inc. (OTCQX: ESBS) (the “Company”) the holding company for Empire State Bank, (the “Bank”) today reported a net loss of $103 thousand, or $0.02 per diluted common share, for the quarter ended March 31, 2024... (continue reading...)

UGI Utilities, Inc. is set to begin a gas main replacement project in Easton on May 20. The work is part of UGI’s commitment to provide safe and reliable service and will impact the following streets:

To view the full announcement, including downloadable images, bios, and more, click here.

John Mason(610) 334-7135[email protected]

Source: UGI Utilities

Distributed by: Reportable, Inc.

ROUND ROCK, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- TSS, Inc. (Other OTC: TSSI), a data center services company that integrates high-performance computing infrastructure and software, reported results for its first quarter ended March 31, 2024.

“We continued to deliver solid financial results with strong growth in revenues, gross profits, operating profits, and Adjusted EBITDA compared to the prior year,” said Darryll Dewan, CEO of TSS. “Executing our... (continue reading...)

Data update expands AML dataset from 5 to 30 patients

LEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.

... (continue reading...)

Human Health Sector

• Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against COVID-19 infection
• Entered into several fully funded vaccine and antibody projects covering more than twelve targets, five of which are funded by two of the top ten pharmaceutical companies
• ... (continue reading...)